Enhancement of67Cu-2IT-BAT-LYM-1 therapy in mice with human burkitt's lymphoma (Raji) using interleukin-2

DeNardo, Gerald L.; Kukis, David L.; DeNardo, Sally J.; Shen, Sui; Mausner, L.F.; O’Donnell, Robert T.; Lamborn, Kathleen R.; Meyers, Frederick J.; Srivastava, Suresh C.; Miers, A B S Laird

doi:10.1002/(sici)1097-0142(19971215)80:12+<2576::aid-cncr33>3.0.co;2-7

Cited by 12 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This modification did not significantly alter immunoreactivity of the antibody [90]. Nude mice bearing human Burkitt's lymphoma (Raji) xenografts treated with 67 Cu-2IT-BAT-Lym-1 achieved high rates of response and cure with modest toxicity [91]. In the pre-clinical radioimmunotherapy comparison with another antibody conjugate, BAT-2IT-IA3, the therapeutic effect of 67 Cu was similar to that of 64 Cu [92].…”

Section: Pre-clinical Studiesmentioning

confidence: 99%

Metal-Based Radiopharmaceuticals in Inorganic Chemistry

2023

View full text Add to dashboard Cite

show abstract

Section: Pre-clinical Studiesmentioning

confidence: 99%

Metal-Based Radiopharmaceuticals in Inorganic Chemistry

2023

View full text Add to dashboard Cite

show abstract

“…Thus, in the past, it has not been possible to provide Cu-67 on a time frame suitable to support clinical trials, with the attendant schedule fluctuations and changing patient status. 22,23 Additionally, the specific activity was at the low end of what was acceptable for antibody therapy, ranging from about 5 to 10 Ci (185-370 GBq) per mg of Cu at EOB. With the construction of a new target station at the IPF at LANL in 2004, the beam intensity and production have improved, but year-round availability still cannot be assured.…”

Section: Copper-67mentioning

confidence: 99%

A Bridge not too Far: Personalized Medicine with the use of Theragnostic Radiopharmaceuticals

Srivastava¹

2013

Journal of Postgraduate Medicine, Education and Research

View full text Add to dashboard Cite

This article deals primarily with the selection criteria, production, and the nuclear, physical, and chemical properties of certain dual-purpose radionuclides, including those that are currently being used, or studied and evaluated, and those that warrant future investigations. Various scientific and practical issues related to the production and availability of these radionuclides is briefly addressed. At brookhaven national laboratory (BNL), we have developed a paradigm that involves specific individual 'dual-purpose' radionuclides or radionuclide pairs with emissions suitable for both imaging and therapy, and which when molecularly (selectively) targeted using appropriate carriers, would allow pre-therapy low-dose imaging plus higher-dose therapy in the same patient. We have made an attempt to sort out and organize a number of such theragnostic radionuclides and radionuclide pairs that may thus potentially bring us closer to the age-long dream of personalized medicine for performing tailored low-dose molecular imaging (SPECT/CT or PET/CT) to provide the necessary pretherapy information on biodistribution, dosimetry, the limiting or critical organ or tissue, and the maximum tolerated dose (MTD), etc., followed by performing higher-dose targeted molecular therapy in the same patient with the same radiopharmaceutical. As an example, our preclinical and clinical studies with the theragnostic radionuclide Sn-117m are covered in somewhat greater detail.A troublesome problem that remains yet to be fully resolved is the lack of availability, in sufficient quantities and at reasonable cost, of a majority of the best candidate theragnostic radionuclides in a no-carrier-added (NCA) form. In this regard, a summary description of recently developed new or modified methods at BNL for the production of five theragnostic radionuclide/radionuclide pair items, whose nuclear, physical, and chemical characteristics seem to show promise for therapeutic oncology and for treating other disorders that respond to radionuclide therapy, is provided.

show abstract

“…In addition it was demonstrated that the therapeutic effectiveness might have been enhanced by recombinant interleukin-2 [56]. In a study in athymic mice implanted with Raji xenografts Cu-67-2IT-BAT-Lym-1 produced a therapeutic and frequently curative effect at tolerated doses.…”

Section: Biological Fatementioning

confidence: 99%

Rhenium-188 and Copper-67 Radiopharmaceuticals for the Treatment of Bladder Cancer

Frier

2004

MRMC

View full text Add to dashboard Cite

The favourable nuclear properties of copper-67 and rhenium-188 for therapeutic application are described, together with methods for the chemical synthesis of a number of derivatives. Survival from invasive bladder cancer has changed little over the past 20 years. The intravesicular administration of Cu-67 or Re-188 radiopharmaceuticals in the treatment of bladder cancer offers some promise for improvement in this situation.

show abstract

Enhancement of67Cu-2IT-BAT-LYM-1 therapy in mice with human burkitt's lymphoma (Raji) using interleukin-2

Cited by 12 publications

References 10 publications

Metal-Based Radiopharmaceuticals in Inorganic Chemistry

Metal-Based Radiopharmaceuticals in Inorganic Chemistry

A Bridge not too Far: Personalized Medicine with the use of Theragnostic Radiopharmaceuticals

Rhenium-188 and Copper-67 Radiopharmaceuticals for the Treatment of Bladder Cancer

Contact Info

Product

Resources

About